



## Adults with Intellectual Disability and ADHD: Clinical characteristics and medication profiles

Journal:	<i>British Journal of Learning Disabilities</i>
Manuscript ID	BLD-18-0047.R2
Manuscript Type:	Original Article
Keywords:	ADHD, Autism, Challenging behaviour

SCHOLARONE™  
Manuscripts

## **Adults with Intellectual Disability and ADHD: Clinical characteristics and medication profiles**

### **Abstract**

The diagnosis of ADHD is often missed or misdiagnosed in people with Intellectual disability (ID). Despite a significant growth in literature on the diagnosis and treatment of ADHD in people without ID, there have been few studies on ADHD in people with ID. In this paper, we describe a group of adults with ID and ADHD open to a specialist community ID service. We examined the frequency and dose of antipsychotic use and considered whether ADHD medication is associated with a reduced use of psychotropic medication. The study found a high incidence of autism in people with ID and ADHD. Men with ID were given the diagnosis of ADHD more often compared to women with ID. Only 36% of people with ADHD and ID taking ADHD medication were on antipsychotic medications compared to 93% of people with ADHD and ID without ADHD medications. This generates several hypothesis such as whether antipsychotic medications are prescribed to control ADHD symptoms, whether use of ADHD medications can reduce the use of antipsychotic medications and/or whether antipsychotics are used to treat underlying psychiatric comorbidities in people with ADHD. Randomised controlled trials are needed to answer the question whether use of ADHD medication reduces use of antipsychotic medication in people with ID and ADHD. Further studies are also needed to explore reason for not using ADHD medication in certain patients with ADHD and ID and what treatment options are effective in treating psychiatric comorbidities in people with ADHD and ID.

### **Accessible summary:**

- ADHD is often missed/underdiagnosed in people with ID compared to people without ID
- Presence of ID, autism and challenging behaviour should raise the suspicion of ADHD as comorbid neurodevelopmental disorder
- Treatment of ADHD in people with ID may reduce the need for antipsychotic medications

## Introduction

### *ADHD in Intellectual Disability*

Intellectual Disability (ID) is defined as a neurodevelopmental disorder with onset during the developmental period with deficits in both intellectual and adaptive functioning in conceptual, social, and practical domains. An overall prevalence of ID in the general population was shown to be approximately 1.04% (Maulik, Mascarenhas, Mathers, Dua, & Saxena, 2011). The presence of one neurodevelopmental disorder (NDD) is known to increase the co-occurrence of other neurodevelopmental disorders (NDD). Therefore, it is important to consider other NDDs in people with intellectual disability.

DSM V defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development (American Psychiatric Association, 2013).

The diagnosis of ADHD in adults requires five or more symptoms to be present in hyperactivity/impulsivity and/or inattention domains and before the age of 12 years. The symptoms must be evident in two or more settings and associated with functional impairment. Although ADHD is commonly associated with children, studies have shown that

1  
2  
3 it persists during adolescence and adulthood in up to two-thirds of individuals and as full or  
4  
5 partial persistence causing a functional impairment (Barkley, Fischer, Smallish, & Fletcher,  
6  
7 2002; Lara et al., 2009).  
8  
9

10  
11  
12  
13 ADHD affects an estimated 3.4% of the adult population with worldwide estimates of 1.2-  
14  
15 7.3% (Fayyad et al., 2007, 2017). It is more prevalent in people with ID compared to the non-  
16  
17 ID population causing a significant functional impairment (Able, Johnston, Adler, & Swindle,  
18  
19 2007). Several studies have shown a higher prevalence of ADHD in adults with ID ranging  
20  
21 from 8.7% - 20.4% (Cantwell, 1996). A Swedish cohort study showed that “people with ID  
22  
23 were at increased risk of ADHD compared to those without ID, and relatives of people with  
24  
25 ID were at increased risk of ADHD compared with relatives of those without ID” (Faraone,  
26  
27 Ghirardi, Kuja-Halkola, Lichtenstein, & Larsson, 2017). Shared genetic risk factors and a  
28  
29 strong familial association may explain the comorbidity between ADHD and ID (Voigt,  
30  
31 Barbaresi, Colligan, Weaver, & Katusic, 2006). Studies comparing people with ID to people  
32  
33 without ID have shown that people with ID continue to have more symptoms of ADHD  
34  
35 compared to people without ID from childhood to adulthood (Xenitidis, Paliokosta, Rose,  
36  
37 Maltezos, & Bramham, 2010). Therefore, the evidence for assessing adults with ID for  
38  
39 ADHD is compelling. Furthermore, it can be argued that diagnosing of ADHD in people with  
40  
41 ID is even more important given it is the only diagnosis among NDDs such as Autism, ID,  
42  
43 dyslexia and dyspraxia which has an evidence-base of effective pharmacological treatments.  
44  
45 For example, a review concluded that psychostimulants (such as methylphenidate,  
46  
47 dexamphetamine, mixed amphetamine salts and lisdexamfetamine) and non-  
48  
49 psychostimulants (such as atomoxetine) are significantly more efficacious than placebo for  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treating ADHD (De Crescenzo, Cortese, Adamo, & Janiri, 2017). Authors also suggested  
4  
5 that there was only preliminary evidence for the effectiveness of non-pharmacological  
6  
7 treatments of ADHD in adults.  
8  
9

### 10 11 12 13 *Under diagnosis of ADHD in ID* 14

15  
16 As highlighted by the World Health Organisation, people with learning disabilities experience  
17  
18 various health inequalities; they have more chronic conditions than the general population,  
19  
20 they develop chronic health conditions at a younger age, and also die sooner following  
21  
22 diagnosis (World Health Organization [and] The World Bank, 2011). Moreover, it has been  
23  
24 reported that there is an increase of ADHD symptoms in ID, which “could not be explained  
25  
26 by inappropriate expectations or by confounding associations with other  
27  
28 emotional/behavioural or cognitive problems” (Simonoff, Pickles, Wood, Gringras, &  
29  
30 Chadwick, 2007) Despite this, ADHD is often considered as under-recognised in people with  
31  
32 intellectual disability (Rose, Bramham, Young, Paliokostas, & Xenitidis, 2009) and  
33  
34 recognising it can be challenging for multiple reasons (Perera & Courtenay, 2017). The core  
35  
36 signs of ADHD of inattention and hyperactivity can also be manifestations of ID (Deb,  
37  
38 Dhaliwal, & Roy, 2008). There is also the added factor of a higher prevalence rate of Autism  
39  
40 in ID, which may make the diagnosis of ADHD even more complex. Problems associated  
41  
42 with ADHD and their presentation are reported to vary depending on age (Montano, 2004;  
43  
44 Rutter et al., 2011) where hyperactivity may present as extreme activity in a younger child  
45  
46 compared to restlessness in an adult. Given that adults with ID have lower intellectual  
47  
48 functioning compared to their chronological age, use of symptoms in adults without ID for  
49  
50 diagnosing ADHD in ID population may not be accurate. The DSM V criteria for ADHD  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 include several symptoms, which can only be detected in people with verbal communication  
4  
5 skills. A majority of people with severe ID have significant deficits in their expressive and  
6  
7 comprehensive communication skills and therefore these criteria may not be applicable  
8  
9 (Perera, 2018). Having a psychiatric co-morbidity can make the diagnosis of ADHD difficult ;  
10  
11 two thirds of people with ADHD have at least one psychiatric comorbidity with an average  
12  
13 number of co-morbidities of 2.4 per person (Piñeiro-Dieguez, Balanzá-Martínez, García-  
14  
15 García, Soler-López, & CAT Study Group, 2016). A high prevalence of mental illness in  
16  
17 people with ID (Cooper, Smiley, Morrison, Williamson, & Allan, 2007) with a co-existent  
18  
19 diagnosis ADHD can complicate the initial diagnosis and subsequent management of these  
20  
21 underlying mental health issues.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 A recent review reported that antipsychotic medications are used in people with ID and  
32  
33 challenging behaviour in the absence of a severe mental illness (Sheehan et al., 2015). In  
34  
35 the ID/ADHD population we hypothesise that antipsychotics are used to manage ADHD  
36  
37 symptoms, where ADHD medication should be the preferred treatment choice.  
38  
39  
40  
41  
42  
43

#### 44 *Study aim*

45  
46 The study is part of a service evaluation project of people with ID and ADHD as a response  
47  
48 to NHS England's 'stopping over medication of people with learning disability, autism or both  
49  
50 with psychotropic medications' (STOMP) campaign to stop the overuse of medications  
51  
52 (NHS, 2018). We aimed to evaluate people with ID and a diagnosis of ADHD and treatment  
53  
54 pathways in a specialist community ID service. We describe characteristics of the group of  
55  
56  
57  
58  
59  
60

1  
2  
3 adults with ID and ADHD; the frequency and dose of antipsychotic; and whether ADHD  
4  
5 medication is associated with reduced psychotropic use.  
6  
7  
8  
9

## 10 **Methods**

### 11 *Study design and sample requirement*

12  
13 A psychiatry case register of people with intellectual disability and mental health difficulties  
14  
15 open to the service were accessed for the period of 1 August 2017 to 1 September 2017.  
16  
17  
18

19 **Inclusion criteria were as follows : 1) Formal diagnosis of intellectual disability 2) age greater**  
20  
21 **than 18 years 3) Confirmed diagnosis of ADHD.** The validity of the diagnoses of ADHD and  
22  
23 ID was confirmed by inspecting the clinical records. Furthermore the diagnosis of ADHD was  
24  
25 confirmed by a consultant psychiatrist in intellectual disabilities using clinical impression and  
26  
27 DSM V criteria. Exclusion criteria included : 1) patients under the age of 18 years 2) unclear  
28  
29 diagnosis of ADHD (insufficient records to make diagnosis/not formally diagnosed by a  
30  
31 mental health professional/not present in adulthood/ insufficient evidence when correlated  
32  
33 with clinical impression and DSM V) 3) borderline intellectual disability 4) Individuals no  
34  
35 longer active on the case register at time of study (travel abroad/non compliance with  
36  
37 service).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 *Setting*

50  
51 The location of the study was in the London Borough of Haringey where over two thirds of  
52  
53 the community are from ethnic minorities and over 100 languages are spoken. In the  
54  
55 borough there are areas of great social deprivation. These socio demographic factors can  
56  
57 add to the complexity of mental health diagnosis and treatment, however the diversity of this  
58  
59  
60

1  
2  
3 study sample makes the findings more applicable to different patient groups given it  
4 represents a group of people with multiple genetic variability to social diversity. The case  
5  
6 series was conducted in Haringey Intellectual Disability services in London, a specialist  
7  
8 integrated Intellectual Disability service providing health and social care inputs to adults with  
9  
10 Intellectual disability living in the borough.  
11  
12  
13  
14  
15  
16  
17

### 18 *Data collection*

19  
20 Data was extracted from the records to include demographic data: age, gender, and severity  
21 of ID (mild, moderate, severe). Severity of ID was determined using intelligence quotient (IQ)  
22 in parallel with the level of adaptive and social functioning for that individual. Information on  
23 comorbid mental health problems (categorised in accordance with DSM V criteria) and  
24 current psychiatric medications (divided into antipsychotics, anxiolytics and hypnotics) were  
25 collected along with the use of stimulant and non-stimulant ADHD medication.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 The frequency and dosage of antipsychotic use in this group was also assessed. Dosage  
40 was given as a percentage of the maximum recommended dose for the antipsychotic in the  
41 British National Formulary (BNF) (Joint Formulary Committee, 2017). This is a reliable tool  
42 for standardizing antipsychotic doses in drug utilization research (Nosè et al., 2008; Sweileh  
43 et al., 2014). When two antipsychotics were used the individual percentages of the maximum  
44 dose were added to give a total percentage. Patients receiving a percentage of BNF  
45 maximum >100% were considered to have a high dose. The medications given and dosages  
46 prescribed vary throughout each individuals treatment pathway. The results described  
47 represent the medication profile at the time of data extraction (1 September 2017).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### *Data analysis*

Data were analysed using SPSS version 20.5. All variables were tested for normality using visual inspection and Shapiro-Wilk test. Differences between the groups were assessed with independent sample t-test. Pearson product-moment correlation coefficient was used to calculate correlation. An independent-sample t-test was conducted to compare antipsychotic dose in patients who were using ADHD medication compared to those who were not. The Shapiro-Wilk test with a Q-Q plot was used to assess for normality. A Pearson product-moment correlation coefficient was also computed to assess the relationship between antipsychotic dose as a percentage of maximum BNF recommended dose compared to ADHD medication dose as a percentage of the maximum BNF recommended dose.

### **Results**

A total of 32 people with ID and ADHD were identified during the study period. Three were excluded as there was an unclear diagnosis as a result of insufficient information on ADHD status in adulthood. Data extraction and analysis were conducted on the remaining 29 cases who met inclusion criteria. Descriptive statistics are presented in Table 1.

The diagnosis of ADHD was 6 times more prevalent in men than women in this group. More than half (55%) had severe intellectual disability. Downs syndrome was present in two cases and Smith Magenis syndrome in one.

**Table 1: Case series characteristics (n = 29)**

Mean Age (Years)	Gender	Severity ID	Co-morbid Diagnoses	Psychotropic use
26.3	Male 25 (86%)	Mild 5 (17%)	Autism 22 (76%)	Antipsychotic 23 (79%)
	Female 4 (14%)	Moderate 8 (28%)	Anxiety Disorder 6 (21%)	Anxiolytics 14 (48%)
		Severe 16 (55%)	Mood Disorder 5 (17%)	Hypnotics 6 (21%)
			Genetic Disorder 3 (10%)	
			Psychotic Disorder 1 (3%)	
			Tic Disorder 2 (7%)	
			Personality Disorder 1 (3%)	

*Co-morbid diagnoses and psychotropic medication*

In this series 22 (76%) met the diagnostic criteria of autism spectrum disorder. Anxiety and mood disorders were the other two most common diagnoses with a prevalence of 21% and 17% respectively. The prevalence of psychotic disorders and personality disorders was 3%. Comorbid psychiatric disorders did not correlate with using psychotropic medication. 79% of people with ADHD were using antipsychotic medication and 48% anti-anxiety medication. Fourteen people (48%) were using ADHD medication and of these 12 (86%) were using Atomoxetine and 2 (14%) Methylphenidate slow release preparations.

#### *Antipsychotic use and ADHD*

The antipsychotic profiles are summarised in tables 2 and 3. Twenty (69%) were using one antipsychotic drug and 3 (10%) were using two antipsychotics. Six (21%) were not using antipsychotic medication. None exceeded the maximum BNF recommended dose with majority (62%) on less than 25% of the recommended maximum dose. Fourteen were using ADHD medication, of which 5 (36%) were not using concomitant antipsychotic. Fifteen people with a diagnosis of ADHD were not using ADHD specific medication but were using antipsychotic medication of whom 3 (20%) were using two antipsychotics. There was no significant difference in antipsychotic dose in those using ADHD medication ( $M=27$ ,  $SD=34$ ) and those not ( $M=28$ ,  $SD=23$ );  $t(27) = 0.145$ ,  $p=0.886$ . There was no correlation between antipsychotic and ADHD medication dose,  $r = -0.201$ ,  $n=29$ ,  $p=0.295$ .

**Table 2: Antipsychotic profile in all patients with ADHD (n = 29)**


Number of antipsychotics	Frequency (n=29)

0	6 (21%)
1	20 (69%)
2	3 (10%)
<b>Percentage of maximum BNF recommended dose</b>	
0-25%	18 (62%)
25-50%	6 (21%)
50-75%	3 (10%)
75-100%	2 (7%)
>100%	0 (0%)

**Table 3: Antipsychotic profile of patients taking and not taking ADHD medication.**

	<b>On ADHD Medication (n=14)</b>	<b>Not on ADHD Medication (n=15)</b>
<b>Number of antipsychotics</b>		
0	5	1
1	9	11
2	0	3
<b>Percentage of maximum BNF recommended dose</b>		
0-25%	9	9
25-50%	1	5
50-75%	3	0
75-100%	1	1

<b>Mean % of maximum dose</b>	27	28
<b>Standard deviation of % of maximum dose</b>	34	23



View Only

## Discussion

The service evaluation has raised important questions with regard to the diagnosis and treatment of ADHD in a group of people with ID and challenging behaviour. We argue that there is not enough emphasis on ADHD as a neurodevelopmental disorder (NDD) in people with ID. Presence of one NDD is known to increase the risk of another NDD. Therefore, given ID as a NDDs, ADHD should be looked into in patients with ID. This is further supported by NICE (2018) Guidelines on ADHD recognising people with ID as a high risk group (NICE, 2018). Autism Spectrum Disorder in ID population is more often recognised and accepted compared to ADHD. Studies have shown that prevalence of ASD in people with ID is to be around 30 - 65% (Clark, Feehan, Tinline, & Vostanis, 1999; Ronald, Simonoff, Kuntsi, Asherson, & Plomin, 2008). **The prevalence of autism in adults with ADHD and ID has not been reported in current literature. However in our series, the prevalence of autism in adults with ID and ADHD was 76%. The high prevalence reported may be a reflection of the increased risk of NDDs seen when one NDD is already present.**

ADHD is diagnosed and treated more often in males than in females with a ratio of approximately 3:1 (Cantwell, 1996). According to Arnett *et al* (2015), males showed more severe symptoms and significantly more variance compared to females (Arnett, Pennington, Willcutt, DeFries, & Olson, 2015) . We observed a higher male: female ratio of 6:1 in people with ID. A similar argument that men with ID show more severe symptoms and more variance which makes it easy to detect ADHD symptoms in men with ID may explain the reasons behind the high male to female ratio in ID in this study.

1  
2  
3 Diagnosis of ADHD can be considered challenging with increasing severity of ID. However,  
4  
5 the majority (83%) in our case series had moderate to severe intellectual disability. This is in  
6  
7 keeping with the current literature where the risk of ADHD increases with the severity of ID  
8  
9 (Voigt et al., 2006). This shows that the diagnosis of ADHD can be considered irrespective of  
10  
11 the severity of ID. Even though the study did not look into subtypes of ADHD , it is likely to  
12  
13 that the diagnosis was made by the behaviour of the individual which meets the criteria for  
14  
15 hyperactivity/impulsivity domain of DSM V criteria.  
16  
17  
18  
19  
20  
21  
22

23 This study raises various clinical conundrums and hypotheses. Challenging behaviour is  
24  
25 common in people with ID. It is defined as “behaviour of an intensity, frequency, or duration  
26  
27 that threatens the physical safety of the person or others or restricts access to community  
28  
29 facilities” (Emerson, 2001). Symptoms of inattention, distractibility, impulsivity, and  
30  
31 hyperactivity in ADHD can be perceived as challenging behaviour in people with ID. Studies  
32  
33 have also shown that children with ID and ADHD are likely to have more conduct problems  
34  
35 compared to children with ADHD without ID (Ahuja, Martin, Langley, & Thapar, 2013).  
36  
37 Authors also reported that the presence of ADHD and ID combination increases the risk of  
38  
39 Oppositional Defiant Disorders and Conduct Disorders compared to children with only ID or  
40  
41 only ADHD. This shows the importance and complexities in diagnosing ADHD in people with  
42  
43 ID along with the high rate of suspicion needed in children with ID for behavioural disorders.  
44  
45 These may result in ADHD being missed in people with ID and challenging behaviour  
46  
47 leading to inappropriate treatments such as use of antipsychotic medications. This may be  
48  
49 one of the explanations for the recent findings that 71% of patients with ID were using  
50  
51 psychotropic drugs without a recorded severe mental illness in order to manage their ‘mood  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 dysregulation' (Sheehan et al., 2015). These findings were also replicated in a study looking  
4  
5 at prescribing in people with autism (Cvejic, Arnold, Foley, & Trollor, 2018). This is also  
6  
7 paralleled by our series where 79% were using antipsychotic medication despite only 3%  
8  
9 having a psychotic disorder. This raises the question why antipsychotic medications are  
10  
11 used in this patient group off label. A case series of 61793 children reported that about 1 in 5  
12  
13 children with a diagnosis of ADHD and long acting stimulant medications were also on a  
14  
15 second generation antipsychotic (Kamble, Chen, Johnson, Bhatara, & Aparasu, 2015).  
16  
17 Studies have also shown that the presence multiple psychiatric comorbidities as a single  
18  
19 most predictor of polypharmacy and off label prescribing (Kearns & Hawley, 2014). This  
20  
21 suggests that antipsychotic medications may be used for different purposes in patients with  
22  
23 ID, ADHD and challenging behaviour. One hypothesis is that antipsychotic medications may  
24  
25 be used to treat underlying comorbid psychiatric disorders such as anxiety disorders.  
26  
27  
28  
29  
30  
31  
32

33 There are several downfalls associated with the use of psychotropic drugs in people with ID  
34  
35 without a severe mental illness. Although psychotropic drugs can reduce anxiety and  
36  
37 improve sleeping patterns, there is no strong evidence base to support use of antipsychotic  
38  
39 medications to treat the core symptoms of ADHD. Long-term antipsychotic use also has  
40  
41 several side effects such as metabolic syndrome, weight gain, hyperprolactinaemia and  
42  
43 sedation (McQuire, Hassiotis, Harrison, & Pilling, 2015). This study showed a clear  
44  
45 difference in the use of antipsychotic medications between the two groups of people with ID  
46  
47 and ADHD who take ADHD medication versus those not on ADHD medications. People who  
48  
49 are not using ADHD medications were more likely to use one or more antipsychotics while  
50  
51 those using ADHD medication used fewer antipsychotic medication. This raises the question  
52  
53 whether ADHD medication use can reduce the use of antipsychotics. This association needs  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to be explored through more robust research methodologies. However, this small case  
4  
5 series suggests that the use of ADHD medications may be beneficial to reduce use of  
6  
7 antipsychotics in people with ID.  
8  
9

10  
11  
12  
13 Stimulant (Methylphenidate) and non-stimulant (Atomoxetine) medication are the main  
14  
15 pharmacological treatment options for ADHD both in the non-ID (Contini et al., 2013) and ID  
16  
17 population (Ji & Findling, 2016). However, less than 50% in our series were using any form  
18  
19 of ADHD medication. The reasons for this may include withdrawal as they progress into  
20  
21 adulthood, lack of efficacy, intolerable side effects, family refusal, and/or clinician oversight.  
22  
23  
24  
25 When comparing people who were using ADHD medication with those without there was no  
26  
27 statistical difference in antipsychotic dose and no correlation between ADHD dose and  
28  
29 antipsychotic dose. However, it is difficult to ascertain whether several confounders such as  
30  
31 severity of ADHD, severity of ID, prescribing clinician, and co-morbid disorders that were not  
32  
33 addressed could have an impact on psychotropic dosing.  
34  
35  
36  
37  
38  
39  
40

41 The effective diagnosis and treatment of ADHD can result in considerably reducing  
42  
43 psychosocial burden. This is of particular importance, as there is a high functional and  
44  
45 psychosocial impairment associated with adult ADHD including parental history of anxiety,  
46  
47 dissatisfaction with love life, and consumption of tobacco (Moulin et al., 2018). Untreated  
48  
49 ADHD could also contribute to functional impairment and occupational outcomes; for  
50  
51 example, a cross-sectional study has demonstrated that “later age of first central stimulant  
52  
53 treatment for ADHD and higher inattentiveness ratings were associated with lower level of  
54  
55 employment” (Gjervan, Torgersen, Nordahl, & Rasmussen, 2012). Prompt treatment can  
56  
57  
58  
59  
60

1  
2  
3 also affect long term outcomes, such as academic, antisocial behaviour, driving, non-  
4  
5 medicinal drug use/addictive behaviour, obesity, occupation, services use, self-esteem, and  
6  
7 social function outcomes; it has been shown that ADHD treatment improved long-term  
8  
9 outcomes compared with non-treatment, even though the outcomes did not reach normal  
10  
11 levels (Shaw et al., 2012).  
12  
13  
14  
15  
16  
17

18 The combination of a high prevalence of ADHD and diagnostic overshadowing in the ID  
19  
20 population warrants the development and routine use of a screening tool for ADHD tailored  
21  
22 specifically towards the ID population. We also suggest that the high rate of co-morbid  
23  
24 autism in ADHD/ID should prompt every clinician in considering autism spectrum disorder as  
25  
26 an additional diagnosis.  
27  
28  
29  
30  
31  
32

### 33 **Limitations**

34  
35  
36 There are several limitations in our study. As this is a local series with a sample size of 29  
37  
38 these findings cannot be generalised to the ID/ADHD population as a whole. The series  
39  
40 used a retrospective medical record review and therefore there may have been incomplete  
41  
42 or missing data as well as difficulty in interpreting or verifying the documented information.  
43  
44  
45  
46  
47

### 48 **Future Research**

49  
50  
51 Although ASD and ADHD are distinct disorders according to DSM-5, there is still a  
52  
53 considerable genetic and clinical overlap between them (Rommelse, Franke, Geurts,  
54  
55 Hartman, & Buitelaar, 2010; Rommelse, Geurts, Franke, Buitelaar, & Hartman, 2011).  
56  
57 Mayes *et al* (2011) reported that children with ADHD did not present with many of the  
58  
59  
60

1  
2  
3 symptoms on the Autism Screening Checklist and therefore children with autism can  
4 distinguished from children with ADHD (Mayes et al., 2011). However, children with Autism  
5 showed some of the symptoms such as inattention, impulsivity, and hyperactivity in maternal  
6 rating scales. Challenges in differentiating the two disorders in clinical practice may result in  
7 people with ADHD either under or over diagnosed in people with Autism. Further studies are  
8 needed to explore symptomatology which can be used to differentiate ADHD from Autism.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Summary**

20 ADHD is a neurodevelopmental disorder which is often neglected in people with ID. There  
21 are diagnostic challenges related to ADHD in ID, however it is an important diagnosis to be  
22 considered given the strong evidence base and national guidelines when diagnosing and  
23 treating ADHD. Autism and ADHD appear to have highly comorbid in people with ID. This  
24 case series showed that only a smaller number of patients who take ADHD medications  
25 were on Antipsychotic medications compared to patients who were not taking ADHD  
26 medications. This raises clinical questions whether ADHD is treated using antipsychotics  
27 rather than evidence based pharmacological treatments as per national guidelines. More  
28 research is needed in people with ID and ADHD.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Bibliography**

- 48 Able, S. L., Johnston, J. A., Adler, L. A., & Swindle, R. W. (2007). Functional and  
49 psychosocial impairment in adults with undiagnosed ADHD. *Psychological Medicine*,  
50 37(1), 97–107. doi:10.1017/S0033291706008713  
51  
52  
53  
54 Ahuja, A., Martin, J., Langley, K., & Thapar, A. (2013). Intellectual disability in children with  
55 attention deficit hyperactivity disorder. *The Journal of Pediatrics*, 163(3), 890–5.e1.  
56  
57  
58  
59  
60 doi:10.1016/j.jpeds.2013.02.043

- 1  
2  
3 American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental*  
4 *Disorders*. (American Psychiatric Association, Ed.) (5th ed.). Washington, DC.  
5  
6  
7 Arnett, A. B., Pennington, B. F., Willcutt, E. G., DeFries, J. C., & Olson, R. K. (2015). Sex  
8 differences in ADHD symptom severity. *Journal of Child Psychology and Psychiatry,*  
9 *and Allied Disciplines, 56(6), 632–639.* doi:10.1111/jcpp.12337  
10  
11  
12  
13 Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002). The persistence of attention-  
14 deficit/hyperactivity disorder into young adulthood as a function of reporting source and  
15 definition of disorder. *Journal of Abnormal Psychology, 111(2), 279–289.*  
16  
17  
18  
19 Cantwell, D. P. (1996). Attention deficit disorder: a review of the past 10 years. *Journal of the*  
20 *American Academy of Child and Adolescent Psychiatry, 35(8), 978–987.*  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- doi:10.1097/00004583-199608000-00008
- Clark, T., Feehan, C., Tinline, C., & Vostanis, P. (1999). Autistic symptoms in children with  
attention deficit-hyperactivity disorder. *European Child & Adolescent Psychiatry, 8(1),*  
50–55. doi:10.1007/s007870050083
- Contini, V., Rovaris, D. L., Victor, M. M., Grevet, E. H., Rohde, L. A., & Bau, C. H. D. (2013).  
Pharmacogenetics of response to methylphenidate in adult patients with Attention-  
Deficit/Hyperactivity Disorder (ADHD): a systematic review. *European*  
*Neuropsychopharmacology, 23(6), 555–560.* doi:10.1016/j.euroneuro.2012.05.006
- Cooper, S.-A., Smiley, E., Morrison, J., Williamson, A., & Allan, L. (2007). Mental ill-health in  
adults with intellectual disabilities: prevalence and associated factors. *The British*  
*Journal of Psychiatry, 190, 27–35.* doi:10.1192/bjp.bp.106.022483
- Cvejic, R. C., Arnold, S. R. C., Foley, K.-R., & Trollor, J. N. (2018). Neuropsychiatric profile  
and psychotropic medication use in adults with autism spectrum disorder: results from  
the Australian Longitudinal Study of Adults with Autism. *BJPsych Open, 4(6), 461–466.*  
doi:10.1192/bjo.2018.64
- De Crescenzo, F., Cortese, S., Adamo, N., & Janiri, L. (2017). Pharmacological and non-  
pharmacological treatment of adults with ADHD: a meta-review. *Evidence-Based Mental*  
*Health, 20(1), 4–11.* doi:10.1136/eb-2016-102415

- 1  
2  
3 Deb, S., Dhaliwal, A. J., & Roy, M. (2008). The usefulness of Conners' Rating Scales-  
4  
5 Revised in screening for attention deficit hyperactivity disorder in children with  
6  
7 intellectual disabilities and borderline intelligence. *Journal of Intellectual Disability*  
8  
9 *Research*, 52(11), 950–965. doi:10.1111/j.1365-2788.2007.01035.x
- 11 Emerson, E. (2001). *Challenging behaviour: Analysis and intervention in people with severe*  
12  
13 *learning disabilities* (2nd ed.). Cambridge: Cambridge University Press.
- 15 Faraone, S. V., Ghirardi, L., Kuja-Halkola, R., Lichtenstein, P., & Larsson, H. (2017). The  
16  
17 Familial Co-Aggregation of Attention-Deficit/Hyperactivity Disorder and Intellectual  
18  
19 Disability: A Register-Based Family Study. *Journal of the American Academy of Child*  
20  
21 *and Adolescent Psychiatry*, 56(2), 167–174.e1. doi:10.1016/j.jaac.2016.11.011
- 23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., ... Jin,  
R. (2007). Cross-national prevalence and correlates of adult attention-deficit  
hyperactivity disorder. *The British Journal of Psychiatry*, 190, 402–409.  
doi:10.1192/bjp.bp.106.034389
- Fayyad, J., Sampson, N., Hwang, I., Adamowski, T., Aguilar-Gaxiola, S., Al-Hamzawi, A., ...  
WHO World Mental Health Survey Collaborators. (2017). The descriptive epidemiology  
of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys.  
*Attention Deficit and Hyperactivity Disorders*, 9(1), 47–65. doi:10.1007/s12402-016-  
0208-3
- Gjervan, B., Torgersen, T., Nordahl, H. M., & Rasmussen, K. (2012). Functional impairment  
and occupational outcome in adults with ADHD. *Journal of Attention Disorders*, 16(7),  
544–552. doi:10.1177/1087054711413074
- Ji, N. Y., & Findling, R. L. (2016). Pharmacotherapy for mental health problems in people  
with intellectual disability. *Current Opinion in Psychiatry*, 29(2), 103–125.  
doi:10.1097/YCO.0000000000000233
- Joint Formulary Committee. (2017). *BNF 74: September 2017*. London: Pharmaceutical  
Press.
- Kamble, P., Chen, H., Johnson, M. L., Bhatara, V., & Aparasu, R. R. (2015). Concurrent use

- of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. *Psychiatric Services*, 66(4), 404–410. doi:10.1176/appi.ps.201300391
- Kearns, M. A., & Hawley, K. M. (2014). Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists. *Journal of Psychiatric Practice*, 20(6), 438–447. doi:10.1097/01.pra.0000456592.20622.45
- Lara, C., Fayyad, J., de Graaf, R., Kessler, R. C., Aguilar-Gaxiola, S., Angermeyer, M., ... Sampson, N. (2009). Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. *Biological Psychiatry*, 65(1), 46–54. doi:10.1016/j.biopsych.2008.10.005
- Maulik, P. K., Mascarenhas, M. N., Mathers, C. D., Dua, T., & Saxena, S. (2011). Prevalence of intellectual disability: a meta-analysis of population-based studies. *Research in Developmental Disabilities*, 32(2), 419–436. doi:10.1016/j.ridd.2010.12.018
- Mayes, S.D., Calhoun, S.L., Mayes, R.D. & Molitoris, S. (2012) Autism and ADHD: Overlapping and discriminating symptoms, *Research in Autism Spectrum Disorders*, 6 (1), 277-285,
- Mayes, S. D., Calhoun, S. L., Murray, M. J., Morrow, J. D., Yurich, K. K. L., Cothren, S., ... Boudier, J. N. (2011). Use of Gilliam Asperger's disorder scale in differentiating high and low functioning autism and ADHD. *Psychological Reports*, 108(1), 3–13. doi:10.2466/04.10.15.PR0.108.1.3-13
- McQuire, C., Hassiotis, A., Harrison, B., & Pilling, S. (2015). Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. *BMC Psychiatry*, 15, 303. doi:10.1186/s12888-015-0688-2
- Montano, B. (2004). Diagnosis and treatment of ADHD in adults in primary care. *The Journal of Clinical Psychiatry*, 65 Suppl 3, 18–21.
- Moulin, F., Chollet, A., Ramos-Quiroga, J. A., Bouvard, M., Melchior, M., & Galéra, C. (2018). Prevalence and Psychosocial Correlates of ADHD Symptoms in Young Adulthood: A French Population-Based Study. *Journal of Attention Disorders*, 22(2),



1  
2  
3 167–181. doi:10.1177/1087054717706758  
4

5 N H S. (2018). NHS England » Stopping over medication of people with a learning disability,  
6 autism or both (STOMP). Retrieved June 19, 2018, from  
7

8  
9 <https://www.england.nhs.uk/learning-disabilities/improving-health/stomp/>  
10

11 NICE. (2018). Attention deficit hyperactivity disorder: diagnosis and management | Guidance  
12 and guidelines | NICE. Retrieved November 19, 2018, from  
13

14  
15 <https://www.nice.org.uk/guidance/ng87>  
16

17  
18 Nosè, M., Tansella, M., Thornicroft, G., Schene, A., Becker, T., Veronese, A., ... Barbui, C.  
19

20 (2008). Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic  
21 dosages? *International Clinical Psychopharmacology*, 23(5), 287–290.  
22

23  
24 doi:10.1097/YIC.0b013e328303ac75  
25

26 Perera, B. & Courtenay, K. (2017). ADHD and challenging behaviour in people with  
27 intellectual disability: should we screen for ADHD?. *Psychiatria Danubina*, 29(3), 274–  
28 484, 562-564  
29  
30  
31

32  
33 Perera, B. (2018). Attention Deficit Hyperactivity Disorder in people with Intellectual  
34 Disability. *Irish Journal of Psychological Medicine*, 1-7. doi:10.1017/ipm.2018.7  
35

36  
37 Piñeiro-Dieguez, B., Balanzá-Martínez, V., García-García, P., Soler-López, B., & CAT Study  
38 Group. (2016). Psychiatric comorbidity at the time of diagnosis in adults with ADHD: the  
39 CAT study. *Journal of Attention Disorders*, 20(12), 1066–1075.  
40  
41

42  
43 doi:10.1177/1087054713518240  
44

45 Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010).  
46

47 Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum  
48 disorder. *European Child & Adolescent Psychiatry*, 19(3), 281–295.  
49

50  
51 doi:10.1007/s00787-010-0092-x  
52

53  
54 Rommelse, N. N. J., Geurts, H. M., Franke, B., Buitelaar, J. K., & Hartman, C. A. (2011). A  
55 review on cognitive and brain endophenotypes that may be common in autism spectrum  
56 disorder and attention-deficit/hyperactivity disorder and facilitate the search for  
57 pleiotropic genes. *Neuroscience and Biobehavioral Reviews*, 35(6), 1363–1396.  
58  
59  
60



1  
2  
3 doi:10.1016/j.neubiorev.2011.02.015  
4

5 Ronald, A., Simonoff, E., Kuntsi, J., Asherson, P., & Plomin, R. (2008). Evidence for  
6 overlapping genetic influences on autistic and ADHD behaviours in a community twin  
7 sample. *Journal of Child Psychology and Psychiatry, and Allied Disciplines*, 49(5), 535–  
8 542. doi:10.1111/j.1469-7610.2007.01857.x  
9  
10  
11  
12

13 Rose, E., Bramham, J., Young, S., Paliokostas, E., & Xenitidis, K. (2009).  
14 Neuropsychological characteristics of adults with comorbid ADHD and borderline/mild  
15 intellectual disability. *Research in Developmental Disabilities*, 30(3), 496–502.  
16  
17  
18  
19  
20  
21 doi:10.1016/j.ridd.2008.07.009

22 Rutter, S. M. J., Bishop, D., Pine, D., Scott, S., Stevenson, J. S., Taylor, E. A., & Thapar, A.  
23 (2011). *Rutter's Child and Adolescent Psychiatry* (5th ed.). John Wiley & Sons.  
24

25  
26 Shaw, M., Hodgkins, P., Caci, H., Young, S., Kahle, J., Woods, A. G., & Arnold, L. E. (2012).  
27 A systematic review and analysis of long-term outcomes in attention deficit hyperactivity  
28 disorder: effects of treatment and non-treatment. *BMC Medicine*, 10, 99.  
29  
30  
31  
32  
33  
34 doi:10.1186/1741-7015-10-99

35 Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., & Horsfall, L. (2015).  
36 Mental illness, challenging behaviour, and psychotropic drug prescribing in people with  
37 intellectual disability: UK population based cohort study. *BMJ (Clinical Research Ed.)*,  
38 351, h4326. doi:10.1136/bmj.h4326  
39  
40  
41  
42

43 Simonoff, E., Pickles, A., Wood, N., Gringras, P., & Chadwick, O. (2007). ADHD symptoms  
44 in children with mild intellectual disability. *Journal of the American Academy of Child and*  
45 *Adolescent Psychiatry*, 46(5), 591–600. doi:10.1097/chi.0b013e3180323330  
46  
47  
48

49 Sweileh, W. M., Odeh, J. B., Shraim, N. Y., Zyoud, S. H., Sawalha, A. F., & Al-Jabi, S. W.  
50 (2014). Evaluation of Defined Daily Dose, percentage of British National Formulary  
51 maximum and chlorpromazine equivalents in antipsychotic drug utilization. *Saudi*  
52 *Pharmaceutical Journal : SPJ : The Official Publication of the Saudi Pharmaceutical*  
53 *Society*, 22(2), 127–132. doi:10.1016/j.jsps.2013.03.003  
54  
55  
56  
57  
58  
59

60 Voigt, R. G., Barbaresi, W. J., Colligan, R. C., Weaver, A. L., & Katusic, S. K. (2006).

1  
2  
3 Developmental dissociation, deviance, and delay: Occurrence of attention-deficit-  
4 hyperactivity disorder in individuals with and without borderline-to-mild intellectual  
5 disability. *Developmental Medicine and Child Neurology*, 48(10), 831–835.  
6  
7  
8

9 doi:10.1017/S0012162206001782  
10

11 Willcutt, E.G. (2012). The prevalence of DSM-IV attention deficit/hyperactivity disorder: A  
12 meta-analytic review. *Neurotherapeutics*, 9, 490–49  
13

14  
15  
16 World Health Organization [and] The World Bank. (2011). *World report on disability*. Geneva,  
17 Switzerland : World Health Organization, [2011] ©2011.  
18

19  
20 Xenitidis, K., Paliokosta, E., Rose, E., Maltezos, S., & Bramham, J. (2010). ADHD symptom  
21 presentation and trajectory in adults with borderline and mild intellectual disability.  
22  
23

24 *Journal of Intellectual Disability Research*, 54(7), 668–677. doi:10.1111/j.1365-  
25 2788.2010.01270.x  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60